Lupin intros generic Noxafil

Sandra Levy
Senior Editor
Sandra Levy profile picture

Lupin is offering posaconazole delayed-release tablets in a dosage strength of 100 mg.

The product is the generic of Merck Sharp & Dohme’s Noxafil delayed-release tablets.

It is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy.

Posaconazole had a market value of roughly $186 million, according to IQVIA December 2020 data.